The stock of TESARO Inc (NASDAQ:TSRO) is a huge mover today! About 453,973 shares traded hands. TESARO Inc (NASDAQ:TSRO) has risen 180.75% since April 5, 2016 and is uptrending. It has outperformed by 178.79% the S&P500.
The move comes after 8 months positive chart setup for the $6.86 billion company. It was reported on Nov, 8 by Barchart.com. We have $179.48 PT which if reached, will make NASDAQ:TSRO worth $2.68B more.
TESARO Inc (NASDAQ:TSRO) Ratings Coverage
Out of 13 analysts covering Tesaro Inc (NASDAQ:TSRO), 11 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 85% are positive. Tesaro Inc has been the topic of 23 analyst reports since August 24, 2015 according to StockzIntelligence Inc. Bank of America initiated TESARO Inc (NASDAQ:TSRO) rating on Tuesday, August 30. Bank of America has “Neutral” rating and $97 price target. Wells Fargo initiated the shares of TSRO in a report on Friday, December 4 with “Outperform” rating. As per Friday, November 4, the company rating was downgraded by Raymond James. The stock of TESARO Inc (NASDAQ:TSRO) has “Outperform” rating given on Friday, November 4 by FBR Capital. The stock has “Buy” rating given by Citigroup on Thursday, March 17. The company was initiated on Thursday, January 21 by Wedbush. The firm has “Outperform” rating by RBC Capital Markets given on Friday, August 12. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, October 10. Leerink Swann maintained the stock with “Outperform” rating in Monday, October 10 report. The firm has “Outperform” rating by Credit Suisse given on Friday, May 13.
According to Zacks Investment Research, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.55 in Q2 2016. Its up 0.32, from 1.23 in 2016Q1. The ratio improved, as 24 funds sold all TESARO Inc shares owned while 36 reduced positions. 34 funds bought stakes while 59 increased positions. They now own 44.90 million shares or 3.32% less from 46.44 million shares in 2016Q1.
America First Inv Advisors Limited Liability last reported 1,000 shares in the company. Nationwide Fund Advsrs last reported 0.01% of its portfolio in the stock. Tocqueville Asset Management Limited Partnership owns 31,750 shares or 0.03% of their US portfolio. Bnp Paribas Invest Partners has invested 0.02% of its portfolio in TESARO Inc (NASDAQ:TSRO). Sandler Cap Mgmt, a New York-based fund reported 17,500 shares. Blackrock Advsrs Limited Liability holds 0.02% or 227,610 shares in its portfolio. Utd Automobile Association reported 26,828 shares or 0.01% of all its holdings. Ameriprise Fincl Inc, a Minnesota-based fund reported 130,322 shares. Two Sigma Lc owns 6,855 shares or 0.31% of their US portfolio. Great West Life Assurance Can has invested 0% of its portfolio in TESARO Inc (NASDAQ:TSRO). Schwab Charles Inv Mngmt has 107,043 shares for 0.01% of their US portfolio. Manufacturers Life Ins The accumulated 17,358 shares or 0% of the stock. Highbridge Cap Management Limited Liability Company owns 42,648 shares or 0.06% of their US portfolio. Bnp Paribas Arbitrage Sa last reported 11,198 shares in the company. Bluestein R H And holds 0.02% or 3,000 shares in its portfolio.
Insider Transactions: Since June 10, 2016, the stock had 0 buys, and 6 sales for $4.43 million net activity. On Tuesday, August 30 the insider Hanke Jeffrey H. sold $2.51M. English Edward C had sold 7,000 shares worth $285,274. Another trade for 327 shares valued at $39,662 was sold by Huber Martin H. Jr..
More recent TESARO Inc (NASDAQ:TSRO) news were published by: Fool.com which released: “Why Tesaro, Inc. Is Skyrocketing 20% Today” on October 10, 2016. Also Investorplace.com published the news titled: “Tesaro Inc (TSRO) Soars on Trial Data, Analyst Upgrades” on October 10, 2016. Investorplace.com‘s news article titled: “Why Alphabet Inc (GOOG), Mylan NV (MYL) And Tesaro Inc (TSRO) Are 3 of Today’s …” with publication date: October 10, 2016 was also an interesting one.
TSRO Company Profile
TESARO, Inc. (TESARO), incorporated on March 26, 2010, is an oncology-focused biopharmaceutical company. The Firm acquires, in-licenses and develops oncology product candidates. The Firm operates in business of developing and commercializing oncology-focused therapeutics segment. The Firm has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.